The phase 3 ATTRACTION-2 (ONO-4538-12) study conducted in Japan, Taiwan, and South Korea was also designed to investigate the efficacy and safety of nivolumab in heavily pretreated patients unselected for PD-L1 tumor expression. The gene discussed is CD274; the disease is neoplasm.